Today, Neuraxpharm launches its Sustainability Report for 2025, highlighting the progress made in our efforts to combine sustainable business practice with innovative CNS solutions.
As Europe’s CNS partner of choice, we are broadening our portfolio of therapeutics, investing in next-generation technologies and new value-added medicines, while remaining committed to minimising our environmental footprint and implementing environmental, social and governance principles across our business.
Read this year’s report, which details our sustainability journey and how we at Neuraxpharm are supporting long-term value for patients, healthcare systems and society.
Looking ahead, we remain confident and motivated in our commitment to delivering better outcomes for people living with CNS conditions whilst continuing to follow the highest standards of corporate sustainability.
